http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System
-
Veracyte to Present at the UBS Virtual Global Healthcare Conference
-
Veracyte Announces First Quarter 2020 Financial Results
-
Veracyte Launches “More About You” Campaign to Educate Patients About Thyroid Cancer Diagnosis
-
CORRECTING and REPLACING Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis
-
Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis
-
Veracyte (VCYT) Announces Prelim. Q1 Results, Withdraws 2020 Financial Guidance
-
Veracyte Announces Preliminary First Quarter 2020 Financial Results and Provides Business Update in Response to COVID-19 Pandemic
-
Veracyte Names Tracy Morris as Vice President of Corporate Communications and Investor Relations
-
Veracyte Announces Novel Gene Fusion Detection with the Afirma Xpression Atlas, Which May Inform Targeted Treatment Decisions for Thyroid Cancer Patients
-
Veracyte Announces Publication of Nearly 700-Patient Study Using Prosigna Breast Cancer Test to Identify Patients Likely to Benefit from Aggressive Chemotherapy
-
Veracyte Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides 2020 Financial Outlook
-
Veracyte to Present at the 9th Annual SVB Leerink Global Healthcare Conference
-
Veracyte to Release Fourth Quarter and Full-Year 2019 Financial Results on February 25, 2020
-
Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma
-
Veracyte (VCYT) Acquires Exclusive License to NanoString (NSTG) Diagnostics Platform
-
Veracyte Acquires Exclusive License to NanoString Diagnostics Platform, Positioning Veracyte To Expand Its Genomic Testing Business Globally
-
Veracyte Announces New Data That Advance Understanding of Genomic Alterations Targeted by Precision Medicine Therapies for Thyroid Cancer
-
Veracyte (VCYT) Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at ATA
-
Veracyte Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association
-
Veracyte Announces Third Quarter 2019 Financial Results and Business Progress
-
Veracyte (VCYT) Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis
-
Veracyte Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis
-
Veracyte Announces Clinical Data Demonstrating Clinical Validity and Utility of Percepta Classifier in Lung Cancer Diagnosis When Bronchoscopy Results Are Inconclusive
-
Veracyte (VCYT) Announces New Data Showing Envisia Genomic Classifier Improves IPF Diagnosis
-
Veracyte Announces New Data Demonstrating That Envisia Genomic Classifier Improves IPF Diagnosis
-
Veracyte to Release Third Quarter 2019 Financial Results and Business Progress on October 22, 2019
-
Veracyte (VCYT) to Announce New Clinical Data for First Noninvasive Nasal Swab Test to Target Early Lung Cancer Detection at CHEST
-
Veracyte to Announce New Clinical Data for First Noninvasive Nasal Swab Test to Target Early Lung Cancer Detection at CHEST Annual Meeting 2019
-
Veracyte Announces Publication of Clinical and Analytical Validation Data for Afirma Xpression Atlas
-
Veracyte (VCYT) Reports Publication of New Study Characterizing Gene Alterations in Thyroid Cancer
-
Veracyte Announces Publication of New Study Characterizing Gene Alterations in Thyroid Cancer
-
Veracyte to Present at Upcoming Investor Conferences
-
Veracyte Announces Second Quarter 2019 Financial Results
-
Veracyte Names Keith Kennedy Chief Operating Officer and Chief Financial Officer
-
Veracyte to Release Second Quarter 2019 Financial Results on July 30, 2019
-
Veracyte Announces Next-Generation Percepta Genomic Sequencing Classifier Now Available to Physicians for Improved Lung Cancer Diagnosis
-
Veracyte Named a San Francisco Bay Area “Top Workplace” For Sixth Consecutive Year
-
Veracyte (VCYT) Reports Publication of Data Detailing Clinical Utility of RNA Sequencing-Based Testing
-
Veracyte Announces New Article Published in Cancer Cytopathology Detailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment
-
Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis
-
Veracyte Announces New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis
-
Veracyte Announces Participation in Two Upcoming Investor Conferences
-
Veracyte Announces New Data Demonstrating Afirma Xpression Atlas’s Potential to Inform Treatment Selection for Patients with Medullary Thyroid Cancer to Be Presented at 2019 ASCO Annual Meeting
-
Veracyte (VCYT) Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis
-
Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis
-
Veracyte Names Sangeeta Bhorade, M.D., Medical Director of Pulmonology
-
Veracyte to Present at the UBS Global Healthcare Conference
-
Veracyte Announces First Quarter 2019 Financial Results
-
Veracyte (VCYT) Receives Regulatory Authorization to Offer Envisia Genomic Classifier for Patients in New York State

